Daniel Thomas O 4

What Happened
Daniel Thomas O, a director of Gossamer Bio, was granted a derivative award to acquire 115,000 shares on June 4, 2026. The filing lists an acquisition price of $0.00 and classifies the item as a derivative (grant/award) made under the company's Non‑Employee Director Compensation Program. This is an award of equity compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears timely).
• Award: rights to 115,000 shares; listed acquisition price $0.00 (derivative security).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 — award made under Non‑Employee Director Compensation Program. F2 — the entire award "becomes fully vested and exercisable" on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service.
• No indication of a 10b5‑1 plan, tax withholding, or immediate sale in this filing.

Context
The filing describes a compensatory equity award to a non‑employee director. Such awards are common as board compensation and do not by themselves indicate buying or selling sentiment. The award is described in the footnote as an option-like award that will vest/become exercisable per the stated schedule; the Form 4 does not show any exercise, sale, or cashless transaction at this time.